Key clinical point: Anlotinib combined with chemotherapy demonstrated good activity in the treatment of metastatic triple-negative breast cancer (TNBC) along with an acceptable safety profile in a single-arm phase 2 study.
Major finding: The median progression-free survival was 8.8 months (95% CI 6.5-11.1 months), and the median overall survival was 19.0 months (95% CI 12.1-25.9 months). Grade 3-4 treatment-related adverse events (TRAE) included neutropenia (22.5%), leukopenia (20.0%), secondary hypertension (10.0%), hand-foot syndrome (5.0%), vomiting (5.0%), proteinuria (5.0%), and thrombocytopenia (2.5%), and no deaths due to TRAE were reported.
Study details: Findings are from a prospective phase 2 trial including 40 patients with metastatic TNBC who were previously treated with anthracycline or taxane and received anlotinib combined with chemotherapy.
Disclosures: This study received funding support from the Shenzhen Basic Research Program, China, and the National Natural Science Foundation of China. The authors declared no conflicts of interest.
Source: Huang JY et al. A single-arm phase II clinical trial of anlotinib combined with chemotherapy for the treatment of metastatic triple-negative breast cancer. Front Oncol. 2023;13:1122294 (Apr 12). Doi: 10.3389/fonc.2023.1122294